

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



三生制药
3SBIO INC.

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1530)

**VOLUNTARY ANNOUNCEMENT
SHENYANG SUNSHINE HAS ENTERED INTO
A COOPERATION AGREEMENT
WITH HAIHE BIOPHARMA IN RESPECT OF
PACLITAXEL ORAL SOLUTION**

Shenyang Sunshine Pharmaceutical Co., Ltd. (“**Shenyang Sunshine**”), a subsidiary of 3SBio Inc. (the “**Company**”), entered into the Paclitaxel Oral Solution Exclusive Commercialization Cooperation Agreement (the “**Agreement**”) with Shanghai Haihe Biopharma Research and Development Co., Ltd. (“**Haihe Biopharma**”) and its subsidiary Shanghai RMX Biopharma Co., Ltd. (“**RMX Biopharma**”). Pursuant to the Agreement, Shenyang Sunshine will obtain the exclusive commercialization rights of RMX Biopharma’s product of Paclitaxel Oral Solution in Mainland China and Hong Kong. Shenyang Sunshine will pay RMX Biopharma an initial payment as well as research and development and sales milestone payments in accordance with the Agreement. RMX Biopharma will continue to be responsible for the ongoing phase III clinical trials and any follow up development, clinical and registration works for the product.

This is a voluntary announcement made by the Company. There is no assurance that the product will eventually be commercialized successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
3SBio Inc.
Dr. LOU Jing
Chairman

Shanghai, the PRC
24 October 2024

As at the date of this announcement, the Board comprises Dr. LOU Jing and Ms. SU Dongmei as executive Directors; Ms. ZHANG Jiaoe as non-executive Director; and Mr. PU Tianruo, Ms. YANG Hoi Ti Heidi and Mr. NG, Joo Yeow Gerry as independent non-executive Directors.